Matthew Cooper

Prof. Matthew Cooper

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRebecca C Coll
Rebecca C Coll
ARAvril Robertson
Avril Robertson
JCJae Jin Chae
Jae Jin Chae
SHSarah C Higgins
Sarah C Higgins
RMRaúl Muñoz-Planillo
Raúl Muñoz-Planillo
Luke O'NeillLuke O'Neill
Luke O'Neill

3 October 2016 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
KBKurtis F. Budden
Kurtis F. Budden
SGShaan L. Gellatly
Shaan L. Gellatly
DWDavid L. A. Wood
David L. A. Wood
MCMatthew Cooper
Matthew Cooper
MMMark Morrison
Mark Morrison
PHPhilip M. Hansbro
Philip M. Hansbro

24 February 2017 in Science
Verified
Journal Article
Closed access
PDF file
JFJosé Javier Fuster
José Javier Fuster
SMSusan MacLauchlan
Susan MacLauchlan
MZMaría A. Zuriaga
María A. Zuriaga
MPMaya N. Polackal
Maya N. Polackal
AOAllison C. Ostriker
Allison C. Ostriker
KWKenneth Walsh
Kenneth Walsh
Faulty blood cells and heart disease: Recent studies have shown that elderly people's blood cells often harbor mutations in genes encoding certain epigenetic regulators. These mutations can lead to clonal expansion of the mutant blood cells, which increases the risk of blood cancers and cardiovascular disease. Fuster et al. generated a mouse model to investigate how one of these genes, Tet2 , affects atherosclerosis development (see the Perspective by Zhu et al. ). They found that the disease progressed more rapidly in mice transplanted with Tet2 -deficient bone marrow cells. This was due to increased secretion of interleukin-1β by Tet2 -deficient macrophages in a process that depended on the action of inflammasomes. Science , this issue p. 842 ; see also p. 798

1 July 2002 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
MCMatthew Cooper
Matthew Cooper

1 April 2016 in Immunity
Verified
Journal Article
Closed access
MGMoritz M. Gaidt
Moritz M. Gaidt
TEThomas S. Ebert
Thomas S. Ebert
DCDhruv Chauhan
Dhruv Chauhan
TSTobias Schmidt
Tobias Schmidt
JSJonathan L. Schmid-Burgk
Jonathan L. Schmid-Burgk
VHVeit Hornung
Veit Hornung

31 October 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RGRichard Gordon
Richard Gordon
EAEduardo A. Albornoz
Eduardo A. Albornoz
DCDaniel C. Christie
Daniel C. Christie
MLMonica R. Langley
Monica R. Langley
VKVinod Kumar
Vinod Kumar
TWTrent M. Woodruff
Trent M. Woodruff
Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease.